A rabies vaccine produced in a non-tumorigenic XXXX cell line.

@entity9058 @entity19 @entity95 @entity17839 @entity291
From the trypsinized skin of a @entity95 embryo, a fibroblastic cell line has been obtained ( @entity9058 cells). The primary seed lot has been established at 11th passage. The tests for tumorigenicity on nu/nu @entity19 were negative (10(4) cell/animal) at passage level 11th and 50th. Cell growth and morphology were not altered when 100 passages were performed. @entity9058 cells were tested for their susceptibility to @entity17839 . The production of virus on @entity9058 cells was investigated after infection by the P.V. @entity17839 adapted to several cell types ( @entity291 fetal kidney, Vero and BHK cells). For the evaluation of an experimental rabies vaccine produced with this substrate, @entity9058 cells were compared to Vero cells. The synthesis of glycoprotein (EIA) and the immunogenicity (NIH test) were similar for the vaccines obtained with both cell systems. @entity9058 cells could therefore be an alternative to Vero cells for the production of a cell culture inactivated rabies vaccine.
